Journal article

Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy

MM Skubisz, AW Horne, TG Johns, UW Nilsson, WC Duncan, EM Wallace, HOD Critchley, S Tong

Obstetrics and Gynecology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013

Abstract

OBJECTIVE: To determine the safety, tolerability, and efficacy of combination gefitinib and methotrexate to treat ectopic pregnancy. METHODS: We performed a phase I, single-arm (nonrandomized), open-label study. Twelve women with ectopic pregnancies were administered methotrexate (50 mg/m2, intramuscular) and 250 mg oral gefitinib in a dose-escalation protocol: one dose (day 1) n53; three doses (days 1-3) n53; seven doses (days 1-7) n56. Efficacy was examined by comparing human chorionic gonadotrophin (hCG) decline and time to resolution with historic controls administered methotrexate only. RESULTS: Common side effects were transient acneiform rash in 67% (8/12) and diarrhea in 42% (5/12) o..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Medical Research Council


Funding Acknowledgements

Supported by National Health and Medical Research Council of Australia (NHMRC) Project Grants #606611 (S. T. and T.G.J.) and #1008276 (S. T., E. M. W., and T.G.J.); NHMRC Career Development Fellowship #1050765 (S. T.); The Monash Institute of Medical Research Flagship Grant (S. T., T.G.J., E. M. W.); Medical Research Council Clinician Science Fellowship (A. W. H.); Medical Research Council Centenary Award #G0802808 (A. W. H.); The Helen MacPherson Trust (S. T.); and The Victorian Government's Operational Infrastructure Support Program (M. S., T.G.J., and E.M.W.).